FIELD: medicine.
SUBSTANCE: invention concerns medicine, namely haematology, cardiology and endocrinology, and covers hyperfibrinogenemia correction in arterial hypertension with impaired glucose tolerance. It is ensured by complex treatment that involves graduated physical activities, as well as introduction of pioglitazone in a dose 30 mg once a day in the morning and lisinopril in a dose 10 mg once a day in the morning during 1.5 months.
EFFECT: invention provides effective correction of fibrinogen level that is ensured by potentiation of therapeutic effect of certain components of complex therapy; than in turn allows reducing risk of thrombotic complications in the given group of patients.
1 ex
